A Phase 2/3 interventional study of MP-214 3mg and MP-214 6mg in Schizophrenia, sponsored by Tanabe Pharma Corporation. Completed at 3 sites in 3 countries. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by Tanabe Pharma Corporation · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.
Among the 23 studies testing cariprazine in Schizophrenia, this one is the 11th largest by enrollment, is one of 5 that started in 2012, is one of 6 in phase 2/3, and was the 10th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in India, Israel
Ages 18–64
Gedeon Richter Plc. · Sites in United States, Bulgaria, Colombia and 5 more countries
Ages 13–17
New York State Psychiatric Institute
Ages 18–55
Bostal Drug Delivery Co., Ltd
Ages 18–65
By country, each count listing its studies:
cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 14
First in 2006; this study’s year is marked. 5 started in 2012.
This study's enrollment of 254 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 129 across the 23 interventional studies. Of the 18 that completed or were terminated, 14 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 23 have an industry lead sponsor. The 10 most frequent:
Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Tanabe Pharma Corporation has 6 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
3 of the studies testing cariprazine in Schizophrenia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT07722728Phase 3Bostal Drug Delivery Co., LtdA Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia | 2027-08 |
| NCT07185815Mapi Pharma Ltd.Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing cariprazine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MP-214 3mg
Drug: MP-214 6mg
Drug: MP-214 9mg
Drug: Risperidone 4mg
In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4. In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
The Numbers show Subjects with at least one Adverse Event
Time frame: Up to 60 weeks (Treatment Period (48 weeks) and Follow-up Period (12 weeks))
| Milestone | MP-214 3mg | MP-214 6mg | MP-214 9mg |
|---|---|---|---|
| Started | 81 | 109 | 58 |
| Completed | 29 | 43 | 34 |
| Not completed | 52 | 66 | 24 |
| Withdrew: Physician decision | 13 | 9 | 6 |
| Withdrew: Withdrawal by subject | 19 | 27 | 8 |
| Withdrew: Adverse event (including death) | 20 | 28 | 8 |
| Withdrew: Protocol violation (including pregnancy) | 0 | 2 | 2 |
The Numbers show Subjects with at least one Adverse Event
| Participants | MP-214 3mg | MP-214 6mg | MP-214 9mg |
|---|---|---|---|
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability | 67 | 92 | 50 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MP-214 3mg | — | 14/81 (17.3%) | 55/81 (67.9%) |
| MP-214 6mg | — | 33/109 (30.3%) | 72/109 (66.1%) |
| MP-214 9mg | — | 14/58 (24.1%) | 42/58 (72.4%) |
| Event | MP-214 3mg | MP-214 6mg | MP-214 9mg |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 9/81 | 26/109 | 11/58 |
| InsomniaPsychiatric disorders | 0/81 | 1/109 | 2/58 |
| Suicide attemptPsychiatric disorders | 0/81 | 2/109 | 0/58 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/81 | 0/109 | 1/58 |
| Completed suicidePsychiatric disorders | 0/81 | 0/109 | 1/58 |
| Schizophrenia, paranoid typePsychiatric disorders | 1/81 | 1/109 | 1/58 |
| Ankle fractureInjury, poisoning and procedural complications | 1/81 | 0/109 | 0/58 |
| Ligament sprainInjury, poisoning and procedural complications | 1/81 | 0/109 | 0/58 |
| ScarInjury, poisoning and procedural complications | 1/81 | 0/109 | 0/58 |
| Skin scar contractureInjury, poisoning and procedural complications | 1/81 | 0/109 | 0/58 |
| Event | MP-214 3mg | MP-214 6mg | MP-214 9mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 21/81 | 13/109 | 13/58 |
| SchizophreniaPsychiatric disorders | 12/81 | 12/109 | 11/58 |
| AkathisiaNervous system disorders | 15/81 | 15/109 | 2/58 |
| InsomniaPsychiatric disorders | 4/81 | 12/109 | 8/58 |
| ConstipationGastrointestinal disorders | 9/81 | 5/109 | 6/58 |
| HeadacheNervous system disorders | 9/81 | 7/109 | 4/58 |
| Tinea pedisInfections and infestations | 0/81 | 3/109 | 6/58 |
| EczemaSkin and subcutaneous tissue disorders | 1/81 | 5/109 | 6/58 |
| Weight increasedInvestigations | 4/81 | 11/109 | 2/58 |
| Extrapyramidal disorderNervous system disorders | 8/81 | 7/109 | 4/58 |
| Age, Continuous(years) | MP-214 3mg | MP-214 6mg | MP-214 9mg | Total |
|---|---|---|---|---|
| Mean | 38.0 ± 11.1 | 40.8 ± 11.3 | 42.5 ± 8.9 | 40.3 ± 10.8 |
| Sex: Female, Male(Participants) | MP-214 3mg | MP-214 6mg | MP-214 9mg | Total |
|---|---|---|---|---|
| Female | 40 | 56 | 20 | 116 |
| Male | 41 | 53 | 38 | 132 |
The record gives a start of Sep 2012, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2021, 4 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine